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Butterfly and Renal Cell Cancer: Out
of Chaos Comes Order
TO THE EDITOR: You are no doubt familiar with the butterfly
effect paradigm to describe the chaos theory. The proverbial but-
terfly flaps its wings on a remote Caribbean island and causes a
hurricane in Europe a few weeks later. A small change in one place
can cause widely diverging outcomes in another. In patients with
cancer the butterfly effect can have devastating effects. Over our
many years of treating cancer, it has become evident that not
everything can be anticipated/predicted but our ultimate goal re-
mains unchanged. It has been said that ‘out of chaos comes order’.
We believe at this important juncture, treatment of renal cell
carcinoma (RCC) requires “order” to be restored.
We have a veritable smorgasbord of potential therapeutic agents
but we are at a loss how best to use them. Three recent papers in the
journal—two clinical trial reports and one opinion piece—highlight
the ongoing dilemmas in RCC management.1-3 Hwang and Heath1
reviewedresultsof recent trials anddiscussed their implicationswithin
the framework of a clinical case with the aim of defining a treatment
algorithm. They suggest a second tyrosine kinase inhibitor (TKI)
following an initial response of greater than 6months and amamma-
lian target of rapamycin when response is less than 6 months. While
this approach is not without its merits, the heterogeneity of RCC and
the lack of comparative data make one hesitate to advocate its wide-
spread adoption.
To comment on the detail—we acknowledge that pazopanib
might be consideredover sunitinib due to its better tolerability but the
lack of data on the former in a patient population with sarcomatoid
features, brainmetastases or with no previous nephrectomy, suggests
that in these subgroups of patients sunitinib is the preferred treatment
approach. We agree that temsirolimus should be considered as stan-
dard in poor-risk patients, but that sunitinib is a good alternative
particularly in patients with normal lactate dehydrogenase and those
with symptoms due to tumor burden, as sunitinib can shrink the
tumor and provide symptomatic relief.
We also consider that the duration of response should be viewed
as a prognostic not a predictive factor to be used in determining
second-line therapy. A prolonged response to a TKI is potentially
associated with a better outcome, independently of subsequent ther-
apies.Patients,whohavenoresponseor a short response toafirstTKI,
in general have amore aggressive disease and as suchmay benefit less
fromsubsequent therapy. Inoureverydayclinicalpracticeweconsider
comorbidities and tolerability of first-line agents when deciding
second-line agents. In addition, in primary resistant patients, we be-
lieve that a more potent TKI such as axitinib, or a chemotherapy
regimen, are more appropriate treatment options. Finally it should
not be forgotten that three or more lines of therapy might be used in
patients with slow, progressive disease.
These are details but to restore order one needs to consider the
bigger picture—what is the overall message we should be giving to
practicingcliniciansonhowtomanagemetastaticRCCandhowtoget
the best out of the plethora of new therapeutic agents? Should we be
developing more andmore complex algorithms with the risk of add-
ing to the “chaos” or would it be opportune, as advocated by our
compatriot,4 to take this opportunity for simplification? The recom-
mendation by Chris Ryan at American Society of Clinical Oncology
nearly5yearsagonow,“. . .useanyagentyouwant,butuse itwell . . .,”5
still holds true today.
We considerwhat there are no inherentwrong choices in the use
of agents to treatRCC,onlyways touse thembetter.Using thembetter
includes toxicity management so that effective dosages of the chosen
agent(s) can be administered—which can be argued is more impor-
tant than the choice of agent.
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